A first-generation antihistamine called brompheniramine is used to treat allergic rhinitis, urticaria, the common cold, and the flu. It is used to treat hay fever, allergic rhinitis, and other upper respiratory allergiesrelated itchy, watery, and runny eyes, nose, and throat symptoms temporarily.
Brompheniramine Dose in Adults
For the symptoms of Cold and flu, allergic rhinitis, and urticaria:
- Immediate release:
- 4 - 8 mg every 4 to 8 hours
- Extended-release:
- 6 - 12 mg every twelve hourly to a maximum dose of 24 mg per day.
Brompheniramine Dose in Childrens
Dose in the treatment of rhinitis and upper respiratory allergies:
- Children 2 - 6 years of age:
- 1 mg (1 mL) orally every 4 - 6 hours to a maximum dose of 6 mg [6 mL] per day.
- Children 6 - 12 years of age:
- 2 mg (2 mL) orally every 4 - 6 hours to a maximum dose of 12 mg [12 mL] per day.
Pregnancy Risk Factor: C
- Although data is not available, it is known that there is a low risk of birth defects in patients who are on first-generation antihistamines.
- It can be used to treat rhinitis and urticaria in pregnant women.
- Patients with intrahepatic-cholestasis are not advised to use antihistamines for itching or pruritis.
Brompheniramine use during breastfeeding:
- Its use during breastfeeding is not well documented.
- Second-generation antihistamines are preferred because of the potential adverse effects in neonates.
- It is important to monitor children for irritability or drowsiness.
- It can also lower serum prolactin levels, and impair lactation.
Brompheniramine Dose in Renal Disease:
- In patients with renal impairment, dose modification is not necessary.
Brompheniramine Dose in Liver Disease:
- It should be used with caution in patients with advanced liver disease and hepatic encephalopathy.
Side effects of brompheniramine (Frequency not defined):
- Cardiovascular:
- Angina Pectoris
- Chest Tightness
- Circulatory Shock
- Extrasystoles
- Hypotension
- Increased Blood Pressure
- Palpitations
- Tachycardia
- Central Nervous System:
- Anxiety
- Ataxia
- Central Nervous System Stimulation
- Chills
- Confusion
- Dizziness
- Drowsiness
- Euphoria
- Excitement
- Fatigue
- Headache
- Hysteria
- Insomnia
- Irritability
- Nervousness
- Neuritis
- Paresthesia
- Restlessness
- Sedation
- Seizure
- Tension
- Vertigo
- Dermatologic:
- Diaphoresis
- Skin Photosensitivity
- Skin Rash
- Urticaria
- Gastrointestinal:
- Abdominal Cramps
- Anorexia
- Constipation
- Diarrhea
- Epigastric Distress
- Heartburn
- Nausea
- Vomiting
- Xerostomia
- Genitourinary:
- Dysuria
- Early Menses
- Urinary Retention
- Hematologic & Oncologic:
- Agranulocytosis
- Hemolytic Anemia
- Hypoplastic Anemia
- Thrombocytopenia
- Hypersensitivity:
- Anaphylactic Shock
- Neuromuscular & Skeletal:
- Tremor
- Weakness
- Ophthalmic:
- Blurred Vision
- Diplopia
- Mydriasis
- Otic:
- Acute Labyrinthitis
- Tinnitus
- Renal:
- Polyuria
- Respiratory:
- Dry Nose
- Dry Throat
- Nasal Congestion
- Thickening Of Bronchial Secretions
- Wheezing
Contraindication to Brompheniramine Include:
- Contraindications are not listed on the label.
Warnings and Precautions
- CNS depression:
- It can cause CNS depression, which may lead to impairment of mental or physical abilities.
- Patients who perform tasks that require mental alertness, such as drivers or heavy-duty workers, should be advised to take the drug with caution.
- Cardiovascular disease
- Patients with hypertension or ischemic heart disease should be cautious about taking the drug.
- Increased intraocular pressure
- Glaucoma patients and those with high intraocular pressure need to be cautious.
- Prostatic hyperplasia, urinary obstruction
- Patients with prostatic hyperplasia and genitourinary retention should be cautious about using the drug.
- Respiratory problems
- Patients who have asthma or chronic bronchitis should not use this drug.
- Thyroid dysfunction:
- Thyroid disease patients should be cautious when using the drug.
Brompheniramine: Drug Interaction
Note: Drug Interaction Categories:
- Risk Factor C: Monitor When Using Combination
- Risk Factor D: Consider Treatment Modification
- Risk Factor X: Avoid Concomitant Use
Risk Factor C (Monitor therapy). |
|
| Acetylcholinesterase inhibitors | Anticholinergic Agents may have a decreased therapeutic effect. Anticholinergic Agents can decrease the therapeutic effects of Acetylcholinesterase inhibitors. |
| Alcohol (Ethyl) | CNS Depressants can increase the CNS depressant effects of Alcohol (Ethyl). |
| Alizapride | CNS Depressants may increase the CNS depressant effects. |
| Amantadine | Anticholinergic Agents may have an enhanced anticholinergic effect. |
| Amezinium | Amezinium may have a stronger stimulatory effect if it is combined with antihistamines. |
| Amphetamines | May lessen antihistamines' sedative effects. |
| Anticholinergic Agents | Other anticholinergic agents could be harmful or poisonous. |
| Betahistine | Betahistine's therapeutic effects may be diminished by antihistamines. |
| Botulinum Toxin-Containing Products | Anticholinergic Agents may have an enhanced anticholinergic effect. |
| Brexanolone | CNS Depressants can increase the CNS depressant effects of Brexanolone. |
| Brimonidine (Topical) | CNS Depressants may increase the CNS depressant effects. |
| Bromopride | CNS Depressants may increase the CNS depressant effects. |
| Cannabidiol | CNS Depressants may increase the CNS depressant effects. |
| Cannabis | CNS Depressants may increase the CNS depressant effects. |
| Chloral Betaine | Anticholinergic drugs could be harmful or poisonous. |
| Chlorphenesin Carbamate | CNS Depressants may have an adverse/toxic effect that can be exacerbated by them. |
| CNS Depressants | Can increase the toxic/adverse effects of CNS Depressants. |
| Dimethindene (Topical). | CNS Depressants may increase the CNS depressant effects. |
| Doxylamine | If taken alongside other CNS Depressants, CNS Depressants may have a stronger CNS depressing impact. Management: The producer of the pregnancy-safe drug Diclegis (doxylamine/pyridoxine) particularly advises against combining it with other CNS depressants. |
| Dronabinol | CNS Depressants may intensify the effects of CNS Depressants. |
| Esketamine | CNS Depressants may intensify the effects of CNS Depressants. |
| Gastrointestinal Agents (Prokinetic) | Anticholinergic Agents can reduce the therapeutic effects of Gastrointestinal Agents (Prokinetic). |
| Glucagon | Anticholinergic agents may increase the toxic/adverse effects of Glucagon. Particularly, there may be an increase in the likelihood of gastrointestinal adverse reactions. |
| HydrOXYzine | CNS Depressants may increase the CNS depressant effects. |
| Itopride | Itopride's therapeutic effects may be diminished by anticholinergic agents. |
| Kava Kava | CNS Depressants may have an adverse/toxic effect that can be exacerbated by them. |
| Lofexidine | CNS Depressants may have a greater depressant effect on the brain. Management: Separate drug interaction monographs are available for drugs listed as an exception to this monograph. |
| Magnesium Sulfate | CNS Depressants may increase the CNS depressant effects. |
| MetyroSINE | MetyroSINE may have a sedative effect that can be enhanced by CNS depressants. |
| Mianserin | Anticholinergic Agents may have an enhanced anticholinergic effect. |
| Minocycline | CNS Depressants may increase the CNS depressant effects. |
| Mirabegron | Anticholinergic agents may increase the toxic/adverse effects of Mirabegron. |
| Mirtazapine | CNS Depressants can increase the CNS depressant effects of Mirtazapine. |
| Nabilone | CNS Depressants may increase the CNS depressant effects. |
| Nitroglycerin | The absorption of Nitroglycerin may be decreased by anticholinergic agents. Anticholinergic Agents may reduce the dissolution sublingual nitroglycerin tablet, which could impair or slow down nitroglycerin absorbtion. |
| Piribedil | CNS Depressants could increase the CNS depressant effects of Piribedil. |
| Pitolisant | Pitolisant's therapeutic effects may be diminished by antihistamines. |
| Pramipexole | Pramipexole may have a greater sedative effect if it is combined with CNS depressants. |
| Ramosetron | Ramosetron's constipating effects may be enhanced by anticholinergic agents. |
| ROPINIRole | CNS Depressants can increase the sedative effects of ROPINIRole. |
| Rotigotine | CNS Depressants can increase the sedative effects of Rotigotine. |
| Rufinamide | CNS Depressants may have an adverse/toxic effect that can be exacerbated by this. Particularly, dizziness and sleepiness may be increased. |
| Selective Serotonin Reuptake inhibitors | CNS Depressants can increase the toxic/adverse effects of Selective Serotonin Resuptake Inhibitors. Particularly, psychomotor impairment could be increased. |
| Tetrahydrocannabinol | CNS Depressants may increase the CNS depressant effects. |
| Tetrahydrocannabinol, and Cannabidiol | CNS Depressants may increase the CNS depressant effects. |
| Thiazide and Thiazide -Like Diuretics | Anticholinergic Agents can increase serum Thiazide or Thiazide-Like Diuretics. |
| Topiramate | Topiramate's toxic/adverse effects may be exacerbated by anticholinergic agents. |
| Trimeprazine | CNS Depressants may increase the CNS depressant effects. |
Risk Factor D (Consider therapy modifications) |
|
| BenzylpenicilloylPolylysine | Antihistamines may reduce BenzylpenicilloylPolylysine's ability to diagnose. Management: Delay testing until systemic antihistaminic effects have subsided and discontinue systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing. A histamine skin test can be used to check for lingering antihistaminic effects. |
| Blonanserin | CNS Depressants can increase the CNS depressant effects of Blonanserin. |
| Buprenorphine | CNS Depressants can increase the CNS depressant effects of buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Buprenorphine patches (Butrans) should be initiated at 5 mg/hr for adults when taken with other CNS depression drugs. |
| Chlormethiazole | CNS Depressants may increase the CNS depressant effects. Monitoring: Look out for signs of CNS depression. If a combination of chlormethiazole and other drugs is required, a reduced dose should be used. |
| Droperidol | CNS Depressants may increase the CNS depressant effects. Management: Droperidol and other CNS agents, such as opioids, may be reduced or used in combination with droperidol. Separate drug interaction monographs provide more detail on exceptions to this monograph. |
| Flunitrazepam | CNS Depressants can increase the CNS depressant effects of Flunitrazepam. |
| Hyaluronidase | Hyaluronidase's therapeutic effects may be diminished by antihistamines. Management: Patients who are taking antihistamines, especially at higher doses, may not have the desired clinical response to the standard doses Hyaluronidase. Higher doses of hyaluronidase might be necessary. |
| HYDROcodone | CNS Depressants can increase the CNS depressant effects of HYDROcodone. When possible, avoid concomitant use with hydrocodone, benzodiazepines, or other CNS depressionants. Combining these agents is not recommended unless there are other options. Limit the amount and duration of each drug when combined. |
| Methotrimeprazine | Methotrimeprazine may have a higher CNS depressant activity than CNS Depressants. Methotrimeprazine can increase the CNS depressant effects of CNS Depressants. Management: Lower the adult dose of CNS Depressants by 50% and start concomitant methotrimeprazine treatment. After clinically proven efficacy of methotrimeprazine, further CNS depressant dose adjustments should only be made. |
| Opioid Agonists | CNS Depressants can increase the CNS depressant effects of Opioid Aggonists. Management: When possible, avoid concomitant use opioid agonists and other CNS depressants. Combining these agents is not recommended unless there are other options. Limit the amount and duration of each drug when combined. |
| OxyCODONE | CNS Depressants can increase OxyCODONE's CNS depressant effects. When possible, avoid the simultaneous use of oxycodone and other CNS depressants. Combining these agents is not recommended unless there are other options. Limit the amount and duration of each drug when combined. |
| Perampanel | CNS Depressants may have a greater CNS depressant effect. Perampanel and any other CNS depressant drug should be used in combination. Patients who take perampanel together with any other drug should not engage in complex or high-risk activities until they have had experience with the combination. |
| Pramlintide | Anticholinergic Agents may have an enhanced anticholinergic effect. These effects are only for the GI tract. |
| Secretin | Secretin's therapeutic effects may be diminished by anticholinergic agents. Concomitant use: Secretin and anticholinergic agents should be avoided. Stop using anticholinergic drugs for at least five half-lives before administering secretin. |
| Sodium Oxybate | CNS Depressants may have a greater depressant effect if taken in combination. Management: Look for alternatives to the combination use. If you must combine use, reduce the doses of any one or more drugs. It is not recommended to combine sodium oxybate and alcohol, or any sedative hypnotics. |
| Suvorexant | CNS Depressants can increase the CNS depressant effects of Suvorexant. Management: Suvorexant or any other CNS depressionant can be reduced in doses. Suvorexant should not be taken with alcohol. It is also not recommended to take suvorexant along with any other drugs for insomnia. |
| Tapentadol | CNS Depressants may increase the CNS depressant effects. Tapentadol, benzodiazepines and other CNS depressants should be avoided when possible. Combining these agents is not recommended unless there are other options. Limit the amount and duration of each drug when combined. |
| Zolpidem | CNS Depressants can increase the CNS depressant effects of Zolpidem. Management: For men who also take CNS depressants, reduce the adult Intermezzo brand sublingual Zolpidem dose to 1.75mg. For women, no dose adjustment is advised. Avoid using CNS depressants at night; do not use alcohol. |
Risk Factor X (Avoid Combination) |
|
| Aclidinium | Anticholinergic Agents may have an enhanced anticholinergic effect. |
| Azelastine (Nasal) | CNS Depressants could increase the CNS depressant effects of Azelastine. |
| Bromperidol | CNS Depressants may increase the CNS depressant effects. |
| Cimetropium | Cimetropium may have an anticholinergic effect that can be enhanced by the use of anticholinergic agents. |
| Eluxadoline | Eluxadoline may cause constipation by using anticholinergic agents. |
| Glycopyrrolate (Oral Inhalation) | Anticholinergic agents may increase the anticholinergic effects of Glycopyrrolate (Oral inhalation). |
| Glycopyrronium (Topical) | Anticholinergic Agents may have an enhanced anticholinergic effect. |
| Oral Inhalation with Ipratropium | Anticholinergic Agents may have an enhanced anticholinergic effect. |
| Levosulpiride | Anticholinergic Agents can reduce the therapeutic effects of Levosulpiride. |
| Orphenadrine | Orphenadrine may be more effective against CNS depression than other drugs. |
| Oxatomide | Anticholinergic Agents may have an enhanced anticholinergic effect. |
| Oxomemazine | CNS Depressants may increase the CNS depressant effects. |
| Paraldehyde | Paraldehyde may be enhanced by CNS depressants. |
| Potassium Chloride | Potassium Chloride may have an ulcerogenic effect that can be exacerbated by anticholinergic agents. Treatment: Patients taking drugs that have significant anticholinergic effects should not consume any oral dose form of potassium chloride. |
| Potassium Citrate | Potassium Citrate may be more ulcerogenic if it is given to anticholinergic agents. |
| Revefenacin | Revefenacin may be enhanced by anticholinergic agents. |
| Thalidomide | CNS Depressants can increase Thalidomide's CNS depressant effects. |
| Tiotropium | Anticholinergic agents may increase the anticholinergic effects of Tiotropium. |
| Umeclidinium | Anticholinergic Agents may have an enhanced anticholinergic effect. |
How to take Brompheniramine?
- Administer the oral solution via the dropper provided by the manufacturer.
Mechanism of action of Brompheniramine:
It inhibits competitively the Histamine (H-1) receptors on effector cells.
39-49 percent of the drug isprotein-boundIt is. It isMetabolizedThe liver is responsible for generating the aforementioned.half-life eliminationChildren spend 12 hours on average and adults spend 25 hours.
TheTime to achieve peak serum concentrationIt takes 3 to 3.5 hours for children and 2-4 hours for adults.
It is primarilyexcretedIn the urine.
International brands of Brompheniramine:
- J-Tan PD
- Respa-BR
- Bomine
- Bromine
- Bromma
- Bromphen
- Broramin
- Dimetane
- Probrom
Brompheniramine Brands in Pakistan:
No brands available in Pakistan
